1. Home
  2. Directory
  3. Massachusetts
  4. Boston
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1609857739

DR. DONALD B BLOCH MD
Prescription History 1609857739
Internal Medicine - Rheumatology in Boston, MA

NPI Status: Active since November 07, 2005

Contact Information

55 FRUIT STREET, YAWKEY 2100
RHEUMATOLOGY ASSOCIATES
BOSTON, MA
ZIP 02114
Phone: (617) 726-7938
Fax: (617) 643-1274

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. DONALD B BLOCH MD, an active Rheumatology specialist practicing in Boston, MA. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 42 documented patient claims. Among these therapy options, the most frequently utilized medication is Enbrel Sureclick, which accounts for 16 claims alone.

Medication Index

E
H
No matching medications currently found on file.

Enbrel Mini

Generic Formulation: EtanerceptSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 310
MA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills25.3
Peer Average Days Supply713
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.2% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $74,789.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,799.01

State Avg Cost Per Claim

$6,970.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant version of soluble human TNF receptor fused to an IgG FC fragment that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS.

Therapeutic Applications

This medication is used alone or in combination with an immunosuppressant (such as methotrexate) to treat certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, and ankylosing spondylitis). Some brands of this medication are also used to treat a skin condition called psoriasis. These conditions are caused by an overactive immune system (autoimmune disease). The immune system attacks the body's own healthy cells, causing inflammation in the joints and skin. Etanercept controls your body's defensive response by blocking the action of a certain natural substance (TNF) that is used by the immune system. Treatment decreases redness, itching and scaly patches in psoriasis as well as the pain, swelling and stiffness of joints in arthritis. This medication can stop the progression of disease and joint damage, resulting in improved daily functioning and quality of life. This medication treats but does not cure autoimmune diseases. Symptoms usually return within 1 month of stopping the medication.

Enbrel Sureclick

Generic Formulation: EtanerceptSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 448
MA State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills43.8
Peer Average Days Supply1,236
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.0% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $123,297.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$7,706.07

State Avg Cost Per Claim

$7,098.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant version of soluble human TNF receptor fused to an IgG FC fragment that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS.

Therapeutic Applications

This medication is used alone or in combination with an immunosuppressant (such as methotrexate) to treat certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, and ankylosing spondylitis). Some brands of this medication are also used to treat a skin condition called psoriasis. These conditions are caused by an overactive immune system (autoimmune disease). The immune system attacks the body's own healthy cells, causing inflammation in the joints and skin. Etanercept controls your body's defensive response by blocking the action of a certain natural substance (TNF) that is used by the immune system. Treatment decreases redness, itching and scaly patches in psoriasis as well as the pain, swelling and stiffness of joints in arthritis. This medication can stop the progression of disease and joint damage, resulting in improved daily functioning and quality of life. This medication treats but does not cure autoimmune diseases. Symptoms usually return within 1 month of stopping the medication.

Hydroxychloroquine Sulfate

Generic Formulation: Hydroxychloroquine SulfateSpecialty: Rheumatology
Provider Metrics Summary
Total Claims 15
30-Day Fills 43.0
Days Supply 1,290
MA State Average Benchmarks
Peer Average Claims78.0
Peer Average 30-Day Fills155.0
Peer Average Days Supply4,594
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 80.8% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $842.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$56.20

State Avg Cost Per Claim

$71.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)

Therapeutic Applications

Hydroxychloroquine is used to prevent or treat malaria caused by mosquito bites. The United States Center for Disease Control provides updated guidelines and travel recommendations for the prevention and treatment of malaria in different parts of the world. Discuss the most recent information with your doctor before traveling to areas where malaria occurs. This medication is also used to treat certain auto-immune diseases (lupus, rheumatoid arthritis). It belongs to a class of medications known as disease-modifying antirheumatic drugs (DMARDs). It can reduce skin problems in lupus and prevent swelling/pain in arthritis. Hydroxychloroquine is not recommended for coronavirus infection, also known as COVID-19, unless you are enrolled in a study. Talk to your doctor about the risks and benefits.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. DONALD B BLOCH MD provides transparency into local medical care patterns within Boston, MA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Rheumatology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.